Juul seeks to extend stay on FDA ban, saying agency did not evaluate all its evidence

Juul seeks to extend stay on FDA ban, saying agency did not evaluate all its evidence


A sign advertising Juul brand vaping products is seen outside a shop in New York City, February 6, 2019.

Mike Segar | Reuters

Juul Labs is seeking to extend a temporary stay on the Food and Drug Administration’s ban of its e-cigarettes, according to a court filing Tuesday.

Juul said in the filing that the agency overlooked more than 6,000 pages of data that it provided about the aerosols generated by heating the liquid in its pods and that users ultimately inhale. The FDA had said last week the company’s application for market approval gave insufficient or conflicting data about the potential risks of using its products, including whether potentially harmful chemicals could leak out of the Juul pods.

A representative for the FDA declined to comment on the filing, saying the agency does not comment on ongoing litigation.

“Had FDA done a more thorough review (like it did for other applicants), it would have seen data showing that those chemicals are not observable in the aerosol that JUUL users inhale,” the company said in the filing with the U.S. District Court of Appeals for the District of Columbia Circuit.

Juul also cited a “backdrop of immense political pressure” that it said influenced the FDA’s decision. It said in its filing that taking its products off store shelves, even temporarily, would permanently damage its brand and that its customers would either use competitors’ products or return to traditional cigarettes.

Over the last year, rival e-cigarette makers British American Tobacco and NJOY have won approvals from the FDA for their e-cigarettes, although the agency rejected some of the flavored products submitted by those companies. The agency said it approved those companies’ tobacco-flavored products because they proved they could benefit adult smokers and outweighed the risk to underage users.

Juul had been the market leader in e-cigarettes since 2018, according to Euromonitor International. As of 2020, the company held 54.7% share of the $9.38 billion U.S. e-vapor market.

The company said that no other rival had their application denied for similar reasons and that the FDA offered no explanation for why it held Juul to a different standard. Juul had been seeking approval for its vaping device and tobacco- and menthol-flavored pods.

Last Thursday, the FDA denied to authorize the products and said the company had to stop selling its products effective immediately. The next day, the Columbia Circuit Court of Appeals granted the emergency request for a stay, pending its appeal of the decision.



Source

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
Health

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of […]

Read More
23andMe CEO Anne Wojcicki ‘surprised and disappointed’ by board resignations: Read the memo
Health

23andMe CEO Anne Wojcicki ‘surprised and disappointed’ by board resignations: Read the memo

Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023.  Jordan Vonderhaar | Bloomberg | Getty Images All seven independent directors of 23andMe resigned from the company’s board Tuesday, a move that CEO Anne Wojcicki said left her “surprised […]

Read More
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Health

Healthy Returns: How competitive can Roche be in the weight loss drug market?

Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain.  Cristina Arias | Cover | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Roche is one of several drugmakers […]

Read More